NCT01511822View on ClinicalTrials.gov

Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance

PHASE4CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
PCOSPolycystic Ovary Syndrome
Interventions
DRUG

Drospirenone Ethinyl estradiol

Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)

DRUG

Drospirenone Ethinyl estradiol Myo-inositol

Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months

DRUG

placebo

Trial Locations (1)

Unknown

Istituto di Patologia Ostetrica e Ginecologica, Catania

All Listed Sponsors
lead

AGUNCO Obstetrics and Gynecology Centre

OTHER

NCT01511822 - Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance | Biotech Hunter | Biotech Hunter